Nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease (NAFLD) in which fat accumulates in the liver causing inflammation, scarring, and other damage. Weight reduction, exercise, cholesterol reduction, and diabetes care can reduce the impact of NASH, but no medications have been approved to treat or reverse the disease. Left untreated, NASH can lead to cirrhosis, liver failure, and liver cancer, as well as an increased incidence of and fatality from cardiovascular disease.
Around 3-12% of adults in the United States have NASH currently. Globally, the NASH drug treatment market is expected to exceed $61 billion (USD) by 2028, with a CAGR of 39.4% over the preceding decade.
Although 3-12% of people in the United States have NASH, with worsening needs and outcomes, no treatments are available.
Current single treatments have proved ineffective in treating NASH, whereas combinations of treatments show promise.
All products currently in development require frequent administration, leading patients to likely have similar adherence issues as those with Type II Diabetes (rates hover around 56% at best for second line treatments).
For patients already taking daily pills, a simple insertion in the doctor’s office avoids the additional burden of weekly injections.
NanoPortal is being designed to last for durations of at least 6 months.
Implantation ensures continuous dosing for the duration of the treatment.